Inari Medical’s top-line growth is primarily driven by its ClotTriever and FlowTriever products that target patients with venous thromboembolism (VTE) (with significant growth opportunities ...

It delivered a trailing four-quarter average earnings surprise of 24.77%. Inari Medical’s top-line growth is primarily driven by its ClotTriever and FlowTriever products that target patients with ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral. Analyst Price Forecast Suggests 14.00% Downside As of December 23, 2024, ...

Inari Medical, Inc. NARI is well-poised for growth on the back of a huge market opportunity for its products and its commitment to understanding the venous system. However, the company’s dependency on ...

In the PEERLESS trial (PEERLESS; 32 Down), the difference was driven by less clinical deterioration and/or bailout as well as less use of intensive care for those treated with the FlowTriever system ...

About Inari Medical, Inc. and Integer Holdings Corporation Inari ... and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a ...

About Inari Medical, Inc., iRhythm Technologies and Inc. Inari ... and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large ...

Post-PERT, there was increased use of percutaneous thrombectomy (FlowTriever [Inari Medical], EkoSonic endovascular system [Boston Scientific Corporation], and occasionally Arrow-Trerotola [Teleflex]) ...

In this article, we are going to take a look at where Inari Medical, Inc. (NASDAQ:NARI) stands against the other small-cap stocks. Wall Street is increasing its bet on small-cap stocks ...